Core Insights - The company reported a revenue of approximately RMB 676.7 million for the six months ending June 30, 2025, representing a year-on-year increase of about 3.7% [1] - The net profit attributable to shareholders increased by approximately 2.1% to around RMB 238.5 million, compared to RMB 233.6 million in the same period last year, after excluding certain non-recurring items [1] - The company submitted 73 patent applications during the period, with 41 patents successfully approved, highlighting its commitment to intellectual property as a key driver of competitiveness in the medical device market [1] Financial Performance - Domestic sales increased by approximately 2.2% compared to the same period in 2024, while overseas sales grew by about 8.0%, attributed to the company's proactive overseas expansion and effective marketing strategies [1] - Non-recurring items included other income from financial assets measured at fair value of approximately RMB 9.9 million, down from RMB 32.9 million in the same period of 2024, and share-based payment expenses of approximately RMB 193.5 million, up from RMB 61.3 million in 2024 [1] Future Outlook - The company will continue to focus on international business expansion while maintaining overall operational efficiency [2] - There is a strong commitment to technological innovation, with ongoing investments in new technology development and product upgrades to meet changing market demands [2] - The company aims to maintain a prudent capital allocation strategy to ensure sustainable growth and create value for all stakeholders [2]
先健科技(01302.HK)公布中期业绩 将继续聚焦国际业务扩张